4/11
08:00 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) is now covered by analysts at BTIG Research. They set a "buy" rating and a $6.00 price target on the stock.
Low
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) is now covered by analysts at BTIG Research. They set a "buy" rating and a $6.00 price target on the stock.
4/3
07:00 am
carm
Carisma Therapeutics to Present at Upcoming Conferences
Low
Report
Carisma Therapeutics to Present at Upcoming Conferences
4/2
09:01 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at HC Wainwright from $11.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at HC Wainwright from $11.00 to $9.00. They now have a "buy" rating on the stock.
4/1
08:35 am
carm
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
High
Report
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4/1
07:00 am
carm
Carisma Therapeutics Announces Changes to its Board of Directors
High
Report
Carisma Therapeutics Announces Changes to its Board of Directors
3/21
05:00 pm
carm
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
2/28
07:30 am
carm
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
Low
Report
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference